2.1 FDA Role, Jurisdiction & Drug Approval

The Food and Drug Administration (FDA) is the federal agency within the Department of Health and Human Services (HHS) responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, the food supply, cosmetics, tobacco products, and products that emit radiation. For pharmacy supply-chain technicians, the FDA's drug-regulation mandate is the most directly relevant: it governs how a product enters the U.S. market, how it must be tracked through distribution, and how suspect or illegitimate product is reported and handled once discovered.

CDER vs CBER: Who Regulates What

Two FDA centers divide human-drug oversight:

• Center for Drug Evaluation and Research (CDER) — regulates the vast majority of prescription and over-the-counter drugs — the small-molecule "pills and capsules" such as atorvastatin, lisinopril, metformin, and oxycodone. CDER reviews New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and many OTC monograph-related matters.
• Center for Biologics Evaluation and Research (CBER) — regulates biological products — vaccines, blood and blood products, allergenics, cellular and gene therapies, and tissue products. Biologics are approved via a Biologics License Application (BLA), not an NDA.

For supply-chain work the distinction matters: a biologic such as a biosimilar infliximab or a vaccine carries different handling, cold-chain, and traceability expectations than a small-molecule tablet — and the approval-pathway label (BLA vs NDA/ANDA) is one way to identify which.

Drug Approval Pathways

How the Pathways Differ in Practice

An NDA sponsor submits full preclinical and clinical data demonstrating the drug is safe and effective for its labeled use. Review can take many months and includes labeling negotiations. An ANDA sponsor does not repeat those trials — it shows the generic is the same as the reference listed drug in active ingredient, dosage form, strength, route of administration, and labeling, and is bioequivalent (same rate and extent of absorption). A BLA is the biologic analog of an NDA; because biologics are made in living systems, the BLA also focuses heavily on manufacturing consistency, potency, and purity — a generic "copy" of a biologic is a biosimilar approved under a separate (not identical) standard.

Rx vs OTC and the Monograph System

OTC drugs reach consumers through one of two routes. The first is conformance to an OTC monograph — a published FDA "recipe book" specifying acceptable active ingredients, doses, formulations, labeling, and testing for a therapeutic class that the agency deems Generally Recognized As Safe and Effective (GRASE). A product that conforms to the monograph can be marketed without a separate application. The second route is an individual NDA — used for newer prescription-to-OTC switches or where the ingredient is not yet in a monograph. Most familiar OTC products — acetaminophen, ibuprofen, antacids, many cough and cold preparations — are marketed under the monograph system.

FDA's DSCSA Oversight Role

Under the Drug Supply Chain Security Act (DSCSA) Title II, the FDA is the federal architect of the U.S. pharmaceutical track-and-trace framework. The FDA's DSCSA responsibilities include:

• Defining the Enhanced Drug Distribution Security (EDDS) requirements — package-level serialization and interoperable, electronic product tracing at the package level — and setting their phased compliance dates (manufacturers and repackagers May 27, 2025; wholesale distributors August 27, 2025; large dispensers November 27, 2025; small dispensers November 27, 2026)
• Receiving suspect and illegitimate product notifications from trading partners (filed using FDA Form 3911)
• Granting waivers, exemptions, and stabilization-period guidance for trading partners
• Setting standards for Authorized Trading Partners and for interoperable electronic methods

The practical takeaway for the PTCB Supply Chain exam: the FDA does not execute every distribution transaction, but it sets the rules every manufacturer, repackager, wholesale distributor, and dispenser must follow so that each package can be traced back to its source and so that suspect or illegitimate product is investigated, documented, and reported. A supply-chain technician's compliance work — verifying T3 (transaction information, history, statement) data, checking serialization, and flagging suspect product — exists because the FDA has defined it as a federal requirement.

Identifying the Approval Pathway in Practice

A supply-chain technician can often tell which pathway a product used from its labeling and packaging. A brand-name product with an NDA number on the label was approved via NDA. A generic product bearing an ANDA number — and usually a statement that it is the generic of a specific reference listed drug — was approved via ANDA. A biologic or biosimilar carries a BLA number and often notes the reference product it is biosimilar to. OTC monograph products typically do not carry an individual application number — they conform to a published monograph. Recognizing these markers helps a technician understand whether a received product is a brand, generic, biologic, or OTC monograph item — which in turn drives handling, storage, and tracing expectations under DSCSA.